All American Society of Hematology news

Yesterday Khang & Khang LLP Announces an Investigation of Agios Pharmaceuticals, Inc. - Business Wire
Yesterday Further research confirms that Verseon’s new class of anticoagulants reduce bleeding risk compared to NOACs by preserving platelet function - Business Wire
2 days ago Kiadis Pharma N.V.: Planned Management Team Changes - Business Wire
2 days ago Astellas Research & Development Meeting Highlights - Business Wire
2 days ago New research reveals role of two genetic mutations in subset of acute myeloid leukemia - News-Medical-Net
3 days ago Lundin Law PC Announces an Investigation of Agios Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm - Business Wire
3 days ago Celltrion Healthcare presenta resultados positivos de CT-P10, candidato a biosimilar de rituximab, para el linfoma folicular de estadío avanzado con diagnóstico reciente - Business Wire
3 days ago Additions to standard therapy do not improve progression-free survival in patients with multiple myeloma - News-Medical-Net
3 days ago Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Agios Pharmaceuticals, Inc. and Certain Officers and Directors - Business Wire
3 days ago Research findings point to inherited genetic basis of ALL risk in children - News-Medical-Net
3 days ago Artificial blood could help paramedics save lives - Daily Mail
3 days ago New immunotherapy shows hope in preventing leukemia relapse - newkerala.com #151521 - New Kerala
3 days ago Experimental T-cell therapy shows promise in preventing AML relapse - News-Medical-Net
3 days ago Dual therapy safe and effective in patients with recurrent Hodgkin lymphoma - News-Medical-Net
4 days ago Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting - Business Wire
4 days ago Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting - Business Wire
4 days ago Celltrion Healthcare presenteert positieve resultaten voor CT-P10, een rituximab biosimilar kandidaat, bij nieuw gediagnosticeerde gevallen van folliculaire lymfoom in een vergevorderd stadium - Business Wire
4 days ago Nordic Nanovector: Betalutin® in Combination with rituximab Demonstrates Synergistic Anti-Tumour Effect in Preclinical non-Hodgkin Lymphoma Model - Business Wire
4 days ago Kiadis Pharma presents positive 1-year follow-up data of its pivotal Phase II trial with ATIR101™ - Business Wire
4 days ago Verastem Presents Phase 2 DYNAMO® Clinical Data at ASH 2016 Annual Meeting - Business Wire
4 days ago Combined Analysis of Oral Epigenetic Therapy, CC-486, Demonstrated Hematologic Responses in Patients Who Received Prior Epigenetic Hypo-Methylating Agents (HMA) - Business Wire
4 days ago KEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology - Business Wire
4 days ago Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting - Business Wire
4 days ago Simple, coordinated approach can improve chances of survival for high-risk AML patients - News-Medical-Net
4 days ago Lundin Law PC Announces an Investigation of Agios Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm - Business Wire
4 days ago H3 Biomedicine Announces Data from Lead Development Program of H3B-8800 in Pre-Clinical Models of Hematologic Cancers - Business Wire
4 days ago Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology - Business Wire
4 days ago Celltrion Healthcare präsentiert positive Ergebnisse für den Rituximab-Biosimilar-Kandidaten CT-P10 zur Behandlung neu diagnostizierter fortgeschrittener follikulärer Lymphome - Business Wire
4 days ago Bellicum Presents Clinical Results to Date of BPX-501 Pediatric Program and Provides Regulatory Update at Investor Event During ASH Annual Meeting - Business Wire
4 days ago Another step closer to artificial blood - KFVS 12 Cape Girardeau
4 days ago Why Agios Pharmaceuticals Inc Stock Fell Sharply Today - FOX Business
4 days ago Why Agios Pharmaceuticals Inc Stock Fell Sharply Today - FOX Business
4 days ago Another step closer to artificial blood - CBS News
4 days ago Celltrion Healthcare presenta i risultati positivi di CT-P10, il biosimilare rituximab candidato, nel trattamento del linfoma follicolare di nuova diagnosi in fase avanzata - Business Wire
4 days ago Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-Treat Chronic Lymphocytic Leukaemia - Business Wire
4 days ago New Drug Effective in 82 Percent of Leukemia Patients - Newsmax
4 days ago Celltrion Healthcare présente des résultats positifs pour le CT-P10 (candidat biosimilaire du rituximab), administré à des patients atteints d’un lymphome folliculaire à un stade avancé nouvellement diagnostiqué - Business Wire
4 days ago Scientists develop device to accurately assess blood's ability to clot - newkerala.com #151118 - New Kerala
4 days ago Novartis says 82 percent of leukemia patients in remission after CAR - FOX News
4 days ago Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-Class Selective RARα Agonist for Genomically Defined Subsets of AML and MDS Patients - Business Wire
4 days ago Celltrion Healthcare Presents Positive Results for CT-P10, Biosimilar Rituximab Candidate, in Newly Diagnosed Advanced Stage Follicular Lymphoma - Business Wire
5 days ago New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients - Business Wire
5 days ago Can Alnylam rise from the ASHes? - MedCity News
5 days ago Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients - Business Wire
5 days ago Researchers develop portable sensor for fast, accurate assessment of blood's clotting ability - News-Medical-Net
5 days ago Combination treatment produces better outcomes in erythropoietin-refractory MDS patients, study shows - News-Medical-Net
5 days ago Clonal hematopoiesis may help predict cancer patients at risk for fatal form of leukemia - News-Medical-Net
5 days ago Hemophilia B patients produce near-normal levels of clotting factor IX after gene therapy, study shows - News-Medical-Net
5 days ago Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology Annual Meeting - Business Wire
5 days ago Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia - Business Wire

Create a custom search

News search supports Google type search formatting and the use of complex boolean. Wrap terms in double quotes for exact phrase matching. Click + to add multiple news search terms to this topic.